Duggan-Keen M F, Brown M D, Stacey S N, Stern P L
Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom.
Front Biosci. 1998 Dec 1;3:D1192-208. doi: 10.2741/a356.
The considerable morbidity and mortality associated with certain human papillomaviruses (HPV) has provided the impetus for HPV vaccine development. The design of such vaccines has evolved from an understanding of the nature of HPV infections and their consequences, together with evaluation of the efficacy of different approaches to vaccination in animal models. These studies have culminated in the production of several different vaccine preparations which are currently undergoing Phase I and II clinical trials. The justification for the widespread implementation of prophylactic HPV vaccines will depend on the outcome of larger scale studies of vaccine efficacy that take into account the epidemiology of HPV infections and associated disease. The usefulness of therapeutic HPV vaccines will require evidence that they can substantially augment or substitute for the effectiveness of currently available treatments.
某些人乳头瘤病毒（HPV）相关的高发病率和死亡率推动了HPV疫苗的研发。此类疫苗的设计源于对HPV感染的本质及其后果的理解，以及对动物模型中不同疫苗接种方法疗效的评估。这些研究最终产生了几种不同的疫苗制剂，目前正处于I期和II期临床试验阶段。预防性HPV疫苗广泛应用的合理性将取决于考虑HPV感染流行病学及相关疾病的大规模疫苗疗效研究结果。治疗性HPV疫苗的有效性需要有证据表明它们能够显著增强或替代现有治疗方法的疗效。
